<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="181436">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732654</url>
  </required_header>
  <id_info>
    <org_study_id>NCT00014511</org_study_id>
    <nct_id>NCT00732654</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy</brief_title>
  <official_title>The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert A. Wood</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Greer Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if small oral and sublingual doses of milk protein
      are safe and effective in decreasing sensitivity to cow's milk in allergic children.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is clinical response to treatment, defined as (1) tolerating ten times the initial oral food challenge threshold dose, OR (2) tolerating the maximum oral food challenge dose at the oral food challenge, at completion of immunotherapy.</measure>
    <time_frame>Approximately 1 1/2 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who maintain a clinical response after withdrawal of treatment for one week.</measure>
    <time_frame>Approximately 1 1/2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who maintain a clinical response after withdrawal of treatment for six weeks.</measure>
    <time_frame>Approximately 1 1/2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all serious adverse events during the study</measure>
    <time_frame>Approximately 1 1/2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all adverse events during the study.</measure>
    <time_frame>Approximately 1 1/2 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Milk Allergy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milk Protein Extract Immunotherapy</intervention_name>
    <description>Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milk Protein Extract Immunotherapy</intervention_name>
    <description>Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milk Powder Immunotherapy</intervention_name>
    <description>Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milk Powder Immunotherapy</intervention_name>
    <description>Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are age 6 to 21 years

          -  Provide signed informed consent (by parent or legal guardian if the subject is a
             minor), and informed assent if applicable

          -  Have a history of symptomatic reactivity to cow's milk (i.e. Eczema, urticaria, upper
             or lower respiratory symptoms, GI disturbances, other rash or oral symptoms)

          -  Have a positive skin prick test (defined as wheal 3 mm ≥ negative control) and cow's
             milk-IgE &gt; 0.35 kIU/L

          -  Have a positive OFC to cow's milk at a cumulative dose of less than 184 milligrams of
             cow's milk intact protein (2,400 mg total milk protein).

          -  Are using appropriate birth control if subject is female and of child bearing age.

          -  Have self-injectable epinephrine (ie. EpiPen® or EpiPen Jr.®) available at home

        Exclusion Criteria:

          -  Have a history of severe anaphylaxis defined as hypoxia (cyanosis or SpO2 ≤ 92% at
             any stage), hypotension, confusion, collapse, loss of consciousness; or incontinence

          -  Have a history of intubation related to asthma

          -  Tolerate more than 184 milligrams of intact cow's milk protein at initial OFC

          -  Are pregnant or lactating

          -  Have a viral URI or gastroenteritis within 7 days of OFC (OFC needs to be
             rescheduled)

          -  Have pulmonary function tests &lt;80% of predicted (FEV1) or clinical history consistent
             with more than moderate persistent asthma

          -  Are currently taking greater than medium dose inhaled corticosteroid (&gt;400 mcg/day
             fluticasone or fluticasone equivalent if ≤ 12 years old or &gt; 600 mcg/day if &gt; 12
             years old)

          -  Are unable to discontinue antihistamines for 5 days for long acting and 3 days for
             short acting prior to skin testing or food challenges

          -  Have used systemic corticosteroids within 4 weeks prior to baseline visit

          -  Are receiving omalizumab, beta-blocker, ACE inhibitor or tricyclic antidepressant
             therapy

          -  Have a chronic disease (other than asthma, atopic dermatitis or rhinitis) requiring
             therapy (e.g., heart disease, diabetes)

          -  Have participated in any interventional study for treatment of a food allergy in the
             past 12 months

          -  Have a severe reaction at initial DBPCFC, defined as either:

        Life-threatening anaphylaxis, or Reaction requiring hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 29, 2012</lastchanged_date>
  <firstreceived_date>August 8, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Robert A. Wood</investigator_full_name>
    <investigator_title>Professor of Pediatrics - Allergy and Immunology</investigator_title>
  </responsible_party>
  <keyword>Food Allergy</keyword>
  <keyword>Oral Immunotherapy</keyword>
  <keyword>Immunoglobulin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
